p300/CBP inhibition enhances the efficacy of programmed death-ligand 1 blockade treatment in prostate cancer

Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibodies has shown to be a promising strategy in cancer therapy, yet clinical response in many types of cancer, including prostate cancer (PCa), is limited. Tumor cells secrete PD-L1 through exosomes or splice variants, which has been de...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jinghui, He, Daheng, Cheng, Lijun, Huang, Changkun, Zhang, Yanquan, Rao, Xiongjian, Kong, Yifan, Li, Chaohao, Zhang, Zhuangzhuang, Liu, Jinpeng, Jones, Karrie, Napier, Dana, Lee, Eun Y., Wang, Chi, Liu, Xiaoqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210073/
https://www.ncbi.nlm.nih.gov/pubmed/32203167
http://dx.doi.org/10.1038/s41388-020-1270-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7210073/
https://www.ncbi.nlm.nih.gov/pubmed/32203167
http://dx.doi.org/10.1038/s41388-020-1270-z

Ejemplares similares